ShareProphets : tidm

JHD

James Halstead plc – its “Trading Update” is a profit warning which dare not speak its name. But…

Floor coverings manufacturer and international distributor James Halstead plc (JHD) has issued a “Trading Update” including that it “has seen continued confidence in the segment of resilient sheet flooring… Cash generation alongside reserves continue to underpin an ungeared balance sheet, which remains strong. The board is confident that the medium-term prospects remain solid”. So what about a current more than 4% lower share price response towards 120p?

By Steve Moore | Published 2026-07-22 13:09:38 |

James Halstead (#JHD) – noting “the recent external challenges… anticipates that sales will be marginally below the 2025 comparative with profit approximately 10-15% below”

2026-07-22 06:31:05

James Halstead (#JHD) – H1 EPS down to 4.4p, DPS slightly up to 2.85p, “backdrop of challenging markets”

2026-03-31 06:33:53

James Halstead (#JHD) – H1 sales and profit “small reduction on comparatives”, states “remains positive for the second half of the year”

2026-01-29 07:35:56

James Halstead (#JHD) – “continue to monitor and control costs” to mitigate effect of Central European and Asia Pacific markets challenges

2025-12-05 07:39:16

James Halstead (#JHD) – FY EPS slightly down to 9.7p, DPS up to 8.8p, states overall this year “expects to make further progress”

2025-10-01 06:32:45

James Halstead (#JHD) – H1 EPS edged up to 5p, DPS to 2.75p, notes “improved margins and reductions in overheads”

2025-03-27 07:34:42

James Halstead (#JHD) – H1 “sales are slightly below last year with profit before tax comparable”

2025-01-31 07:39:52

James Halstead (#JHD) – trading “on track to meet our expectations of continued progress”, “remain positive about the market”

2024-12-06 07:34:17

James Halstead (#JHD) – expects FY profit in line with the increased market expectations, notes commercial flooring resilience

2024-07-31 06:47:49

James Halstead (#JHD) – H1 EPS up to 4.8p, DPS to 2.5p, performance continuing in early months of H2

2024-03-27 07:25:01

James Halstead (#JHD) – H1 profit “15-20% ahead of the prior year comparative… despite softening of sales demand in some European markets”

2024-01-31 07:30:39

James Halstead (#JHD) – five months “improved output and profits which are materially ahead of the comparatives”

2023-12-01 07:29:16

James Halstead (#JHD) – FY EPS +5% to 10.2p, DPS +3% to 8p, remains confident in progress

2023-10-02 06:27:57

James Halstead (#JHD) – FY “positive” sales demand, latter months helped by easing of electricity and shipping & transportation costs

2023-08-01 06:39:41

James Halstead (#JHD) – H1 EPS reduced to 4.3p, DPS maintained at 2.25p, notes some outlook encouragement including recent sales

2023-03-31 06:37:23

James Halstead (#JHD) – H1 PBT slightly short of comparative period, positive FY outlook unchanged

2023-02-02 07:27:57

James Halstead (#JHD) – FY profit slightly up, recent trading “positive” but notes costs challenges

2022-10-03 07:29:59

James Halstead (#JHD) – notes FY sales growth but various trading challenges

2022-08-01 07:50:07

Stocks I still love include Tate & Lyle and James Halstead

As noted back in November, I am a fan of Tate & Lyle (TATE) shares so it is pleasing to see them up 8% odd year-to-date. There are a bunch of reasons for this as I observed nearly five months ago, but the news today is that it’s buying a "leading prebiotic dietary fibre business in China from ChemPartner Pharmatech Co., Ltd for a total consideration of US$237 million". It is far from a boring thing to do, in fact - for a company which is outsourcing the management of much of its core historic business shortly - it is actually quite interesting to help it access more of the Asian/emerging market world over time. I remain a fan. And what also about James Halstead (JHD), “the AIM listed manufacturer and international distributor of commercial floor coverings”, whose shares are most certainly not up year-to-date?

By Chris Bailey | Published 2022-03-31 12:45:53 |

previous 0 Page 1 of 3 (51 articles) next 20

Latest News

Show All

UPDATED: Lucian Miers & Jim Mellon are coming back to Sharestock in 2027: early bird tickets now on sale, event 15% sold out!

Tom Winnifrith Bearcast: the Sydney Sweeney row with the Mrs and daughter 2

Evil Banksta weighs in on TekCapital after today’s spooftastic RNS

Good news travels fast but bad news….the case of Skinbiotherapeutics

Mothercare: the end is nigh, don’t blame Trump, I told y’all eons ago

EXPOSE: Nuburu shares in a slump post relisting on American Stock Exchange and latest accounts contain a material error

Letter to Pointon Young, former auditors to Amazing AI

Reinvesting my Satsuma Winnings

Tribal Group – “Proposed Acquisition by Main Capital Partners” provides us with another share tip winner

Quantum Data Energy - why are its shares still suspended?

Recent Comments

TOM18 Sep 2026

a shareholder could call a meeting to propose new directors by PM & pals own 50% of the equity sod vote it down

Letter to Pointon Young, former auditors to Amazing AI

AIMINVESTOR18 Sep 2026

This makes a mockery of the the so called rules and regulations when something as blatant as this is done.It's a shame a shareholder can't propose themselves as a director just to prevent the strike-off.Is there nothing legal that can be done at this point?

Letter to Pointon Young, former auditors to Amazing AI

TOYIN18 Sep 2026

Thanks Tom, just picked some more up sub 8p.

Good news travels fast but bad news….the case of Skinbiotherapeutics

JOHN BROWN18 Sep 2026

It's outrageous that the likes of Amy Hunt claim that women with Sydney Sweeney's body shape cannot play sport. Who said that sportswomen can't look like Ms Sweeney?

Tom Winnifrith Bearcast: the Sydney Sweeney row with the Mrs and daughter 2

MICKTHELINGE18 Sep 2026

If it gets to 3p then construction will be going well and it will be well on the way to 6p+ so interested in why you would sell out then?

Reinvesting my Satsuma Winnings

TOM18 Sep 2026

Whatever Opti's intentions it will have to sell.You could say you should sell now as maybe your last chance to sell at above 8oops too late, now 7.5p to sell

Good news travels fast but bad news….the case of Skinbiotherapeutics

DUCKnDIVE18 Sep 2026

I thought that a seasoned reader of financial statements would have clocked that OPTI's HY results to 30/6/26 classed their SBTX shares as non-current assets – meaning that management has no intention to sell them within 12 months.Maybe you assumed that they were forced to class them as non-current because SBTX shares were suspended…but no, the SBTX suspension was lifted weeks before OPTI's sign-off date.And if you believe that OPTI haven't sold all or most of their remaining SBTX shares since June 30th, I'm afraid they saw you coming.There is of course a risk that OPTI has double accounted for its SBTX shares, having included them in both non-current assets and in "cash and equivalents", which might be a fruitful line of enquiry for you.As for Skin's RNS arriving a day outside the standard 10th-20th definition of mid-month, they have had a lot of balls to juggle so a 24hr delay ought to be a cause for congratulations.Why not grab some SBTX shares this afternoon? Could be your last chance to buy back below 12p.

Good news travels fast but bad news….the case of Skinbiotherapeutics

DUCKnDIVE18 Sep 2026

Notwithstanding your ad nauseam negativity on SBTX, I choose to believe the positive indications from the 8 June RNS, including "Growth continued across the company", under Current Trading and Outlook (from a chairman who never speaks with forked tongue). Accordingly, I have helped myself to a nice top-up in anticipation of a welcome trading update on Monday.

Tom Winnifrith Bearcast: Hang on for the PS in the podcast

BOBINS18 Sep 2026

lets hope the Houthis keep away from the Saudi Mines?

Reinvesting my Satsuma Winnings

Charles18 Sep 2026

Easy work for the FCA with you having laid it out.

EXPOSE: Paul Mathieson and the strike off: you might think that, I could not comment